PATH (3840) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Despite higher revenue, the operating loss expanded substantially due to a sharp increase in SG&A expenses, making the disconnect between revenue growth and improved profitability the most important point in this quarter. Revenue was ¥1.79B (+7.0% YoY), Operating Income was ¥-0.52B (a ¥0.37B deterioration from ¥-0.15B in the prior year), Ordinary Income was ¥-0.52B, and Net Income was ¥-0.52B (a ¥0.22B deterioration from ¥-0.19B in the prior year). While the gross margin remained broadly in line with the prior year at 51.8%, SG&A expenses increased +42.1% YoY, substantially outpacing revenue growth and representing the primary cause of the wider operating loss.

Factors Affecting Earnings

【Revenue】Revenue was ¥1.79B, up +7.0% YoY. By segment, the Cosmetics Business generated ¥0.73B (40.6% of total, +16.3%), the Beauty & Wellness Business generated ¥0.63B (35.0%, -20.0%), the Regenerative Medicine-Related Business generated ¥0.37B (20.6%, +38.9%), the AI & Technology Business generated ¥0.04B, and the Investment Business generated ¥0.03B (approximately 14 times the prior-year level). The decline in revenue from the core Beauty & Wellness Business was offset by higher revenue from the Cosmetics, Regenerative Medicine, and new businesses.

【Profit and Loss】Operating Income was ¥-0.52B, deteriorating by ¥0.37B from ¥-0.15B in the prior year, while the operating margin was -29.0% (approximately 1,990pt worse than -9.1% in the prior year). The gross margin of 51.8% was broadly unchanged from the prior year, but the SG&A ratio rose to 80.8% from 60.9%, representing the primary cause of the deterioration in profitability. By segment, the Cosmetics Business’s loss widened from ¥0.026B to ¥0.162B, while the Beauty & Wellness Business moved from a ¥0.032B profit to a ¥0.066B loss. Only the Investment Business generated a profit of ¥0.028B, which was insufficient to offset the consolidated loss, resulting in higher revenue but lower earnings.

Segment Analysis

Of the seven segments, only the Investment Business generated Operating Income (revenue of ¥0.03B, profit of ¥0.028B, and a profit margin of 94.3%). The Cosmetics Business recorded higher revenue but an expanded loss (revenue of ¥0.73B, loss of ¥-0.162B, and a profit margin of -22.2%), while the Beauty & Wellness Business moved from profitability to a loss in addition to lower revenue (revenue of ¥0.63B, loss of ¥-0.066B, and a profit margin of -10.5%). The Regenerative Medicine-Related Business showed signs of improved profitability, with its loss ratio improving to 7.0% from 10.0% in the prior year as revenue increased. The AI & Technology Business (profit margin of -234.9%), Sustainable Business, and Market Expansion Business remain small in scale and bear a heavy fixed-cost burden.

Key Financial Indicators

【Profitability】The operating margin of -29.0% and net profit margin of -28.9% both deteriorated substantially from the same period of the prior year (approximately -9.1% and -11.6%, respectively). The gross margin remained at 51.8%, indicating that the increase in the SG&A burden, rather than cost of sales, was the primary cause of the deterioration in profitability. 【Cash Flow Quality】Cash and deposits stood at only ¥0.14B, while ¥0.68B in inventories and ¥0.75B in construction in progress remained tied up. 【Investment Efficiency】Annualized ROE was -28.7%, reflecting both the erosion of net assets and losses from the core business. EPS was ¥-6.84 (¥-3.21 in the prior year), while BPS was ¥30.72 (¥33.47 in the prior year). 【Financial Soundness】The Equity Ratio declined to 68.6% from 75.5% in the prior year but remained high. Current assets of ¥1.46B versus current liabilities of ¥0.44B indicate ample liquidity; however, interest-bearing debt, including ¥0.46B in bonds, requires monitoring while the Company remains in operating deficit.

Cash Flow Analysis

Although the statement of cash flows has not been disclosed, trends in the balance sheet indicate that cash and deposits declined from ¥0.15B in the prior year to ¥0.14B. Meanwhile, inventories increased to ¥0.68B, and construction in progress increased to ¥0.75B (up ¥0.23B from ¥0.52B in the prior year), indicating increasing funds tied up in working capital and capital expenditures. Accounts payable declined 37.6% from ¥0.18B to ¥0.11B, with the reduction in trade payables increasing the funding burden on working capital. With operating losses continuing, the Company appears to be using interest-bearing debt, including ¥0.46B in bonds, to support asset growth.

Quality of Earnings

The expansion of the loss during the current period was caused not by non-operating or extraordinary gains and losses, but by increased SG&A expenses in the core business, and should therefore be viewed as a decline in recurring earnings power. Non-operating income was ¥0.01B and non-operating expenses were also ¥0.01B, leaving Ordinary Income at approximately the same level as Operating Income at ¥-0.52B. Extraordinary income of ¥0.01B, including gains on the sale of fixed assets, made only a limited contribution to the loss before tax, and distortions from temporary factors were minor. Comprehensive Income was ¥-0.52B, approximately equal to Net Income attributable to owners of the parent, with no material divergence arising from other comprehensive income items. The nature of the loss therefore reflects the underlying performance of the core business.

Earnings Forecast and Guidance

The full-year company forecast is Revenue of ¥2.84B (+26.0% YoY), Operating Income of ¥-0.48B, Ordinary Income of ¥-0.50B, forecast EPS of ¥-6.57, and forecast dividends of ¥0 per share. The Q3 year-to-date revenue progress rate was 63.2%, 11.8pt below the standard 75%, while the operating loss (¥-0.52B) and net loss (¥-0.52B) have already exceeded the full-year forecasts. Unless substantial revenue growth and a reduction in losses are achieved in Q4, progress toward achieving the full-year forecast remains challenging. No revision to the earnings forecast was made during this quarter.

Shareholder Returns

Both the Q2 dividend and the full-year forecast dividend are ¥0 per share, and the Company continues to pay no dividends. Given the cumulative net loss of ¥0.52B and retained earnings of ¥-2.83B, the Payout Ratio is effectively 0%, and the financial structure prioritizes maintaining internal funds for the foreseeable future. No disclosure regarding share repurchases has been made, and there is no basis for calculating the Total Return Ratio.

Risk Factors

1. Deterioration in the profitability of core businesses: The Cosmetics Business increased revenue by +16.3%, but its loss expanded from ¥0.026B to ¥0.162B. The Beauty & Wellness Business also experienced a -20.0% decline in revenue and moved from a ¥0.032B profit to a ¥0.066B loss, indicating a structural issue in which revenue growth does not translate into profits.

2. Accumulation of inventory and working capital: Inventories amounted to ¥0.68B, representing 19.2% of total assets, while accounts payable declined -37.6% YoY. Inventory accumulation and the reduction of trade payables are occurring simultaneously, and declining working capital efficiency could affect cash management.

3. Risk of delayed operation of construction in progress: Construction in progress increased to ¥0.75B (+42.9% YoY), accounting for 44.9% of property, plant and equipment. If the completion, commencement of operations, or monetization of the investment is delayed, this could lead to delayed recovery of invested capital and future impairment risk.

Industry Benchmark (For Reference; Company Analysis)

Industry Benchmark (it_telecom)

Profitability and Returns

Profitability was substantially below the industry median, with both the operating and net profit margins ranking near the bottom among peers.

Growth and Capital Efficiency

The revenue growth rate was slightly below the industry median, leaving growth at an average level among peers.

※Source: Company analysis

Key Takeaways from the Financial Results

1. Revenue increased +7.0%, but the operating loss widened to ¥0.52B. With the gross margin maintained at 51.8%, the primary cause of the deterioration in profitability was the +42.1% YoY increase in SG&A expenses.

2. While only the Investment Business generated Operating Income of ¥0.028B, this was insufficient to offset the expanding losses in the Cosmetics, Beauty & Wellness, and AI & Technology businesses. Improving the profitability of the overall business portfolio will be the key focus going forward.

3. The full-year revenue progress rate was 63.2%, below the standard progress rate of 75%, while the operating and net losses have already exceeded the full-year forecasts. Funds tied up in inventories of ¥0.68B and construction in progress of ¥0.75B remain subject to ongoing monitoring from the perspective of capital efficiency.

Theoretical Share Price (Reference Value)

Sensitivity: ¥10–¥11 at Cost of Equity ±1%, and ¥10–¥11 at ω±0.1.

Notes:

• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the end of the quarter are used; there is a timing difference from the full-year forecast.

(Valuation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data and is not a forecast of the market share price or a recommendation of any specific investment action; it does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting professionals as necessary.

---End of Report---